MOUNTAIN VIEW and LA JOLLA, Calif. - Oct. 3, 2011 - Complete Genomics Inc. (NASDAQ: GNOM), the whole human genome sequencing company, and the not-for-profit Scripps Health system today announced a major collaboration that will help further the Wellderly Study, a landmark scientific research initiative aimed at unlocking the genetic secrets of lifelong health.
Under the collaboration, Complete Genomics will sequence, at its own cost, the whole human genomes of 1,000 participants in the Wellderly Study. The Wellderly Study is headed by Scripps Health Chief Academic Officer Dr. Eric J. Topol, who has spent the past four years recruiting healthy elderly individuals who are at least 80 years old and free from major diseases and long-term medications. The median age of this study group is 87, and participants range up to 108 years old.
"There have been a significant number of longevity studies, but the Wellderly Study is the first one focused specifically on healthy aging," said Dr. Topol. "Furthermore, through our partnership with Complete Genomics, we are now conducting the largest whole genome study of a single phenotype - healthy lifespan or healthspan. We anticipate that by employing Complete Genomics' sequencing service, and being able to study participants' entire genome for the first time, we will gain valuable insights into the genetic variants that have helped protect the health of our Wellderly population."
The purpose of the Wellderly Study is twofold. First, it is to uncover the genetic underpinnings of healthy life span, which likely involve guardian genes that protect against chronic diseases. Second, healthy older individuals are ideal controls for genetic studies of late-onset diseases such as various cancers, heart disease, Alzheimer's disease and Parkinson's disease.
In addition to sequencing the whole genomes of these 1,000 Wellderly Study participants, Complete Genomics will work with Scripps to assemble the results into a Wellderly Genomic Reference Resource, which may have broad applicability in the field of translational medicine.
"This resource of universal controls will be extremely valuable to other research groups that are using sequencing to understand the genomic root causes of diseases," said Dr. Nicholas Schork, director of research of the Scripps Translational Science Institute (STSI). STSI is a major research initiative of Scripps Health, in collaboration with The Scripps Research Institute.
This study is now possible because the cost of whole human genome sequencing has decreased dramatically over the past few years, while the accuracy and efficiency of the technology has continued to increase. For example, it cost $3 billion to sequence the first human genome via the Human Genome Project in 2000. Just two years ago, Complete Genomics was charging $20,000 to sequence a human genome, and that price is now reduced to $5,000 apiece for small orders and $4,000 each in volume.
Dr. Clifford Reid, the CEO of Complete Genomics, added, "What could be more exciting than to be working with Dr. Topol and his colleagues at Scripps to discover what makes people healthy into their 80s and beyond? Now that Complete Genomics has made whole human genome sequencing affordable, accurate and scalable, we have the opportunity to uncover what's special in the genetic makeup of this extraordinarily healthy group of individuals."
Another valuable aspect of the Reference Resource will be the addition of Cypher Genomics clinical annotations to the sequencing datasets. Cypher Genomics is a project headed by Drs. Schork and Topol, as well as STSI faculty member Dr. Ali Torkamani and STSI industry liaison Dr. Ashley Van Zeeland. STSI has developed and plans to commercialize this software suite for annotating genomic variant lists with clinically relevant pathway and disease prediction information.
"The addition of Cypher Genomics annotations to the Reference Resource will provide researchers with a significant head start when they are looking to identify specific mutations that either cause or, in some cases, prevent the onset of specific diseases," said Dr. Torkamani, director of drug discovery at STSI.
The Wellderly Genomic Reference Resource, which will contain sequence data, variant lists and clinical annotations from more than 1,000 individuals, will be available exclusively from Complete Genomics.
The Wellderly Study is an ongoing project with the goal of enrolling 2,000 elderly volunteers to donate their DNA to the program's gene bank. People who meet the study criteria and are interested in participating are encouraged to call 1-800-SCRIPPS (1-800-727-4777) or send an email to firstname.lastname@example.org.
About Complete Genomics
Complete Genomics is a whole human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. Its Complete Genomics Analysis Platform (CGA™ Platform) combines Complete Genomics' proprietary human genome sequencing technology with advanced informatics and data management software. The company offers its solution as an innovative, end-to-end, outsourced service, CGA™ Service, and provides customers with data that is immediately ready for genome-based research. Additional information can be found at http://www.completegenomics.com.
About Scripps Health
Founded in 1924 by philanthropist Ellen Browning Scripps, Scripps Health is a $2.3 billion nonprofit integrated health system based in San Diego, Calif. Scripps treats a half-million patients annually through the dedication of 2,600 affiliated physicians and 13,000 employees among its five acute-care hospital campuses, home health care services, and an ambulatory care network of physician offices and 23 outpatient centers and clinics.
Recognized as a leader in the prevention, diagnosis, and treatment of disease, Scripps is also at the forefront of clinical research, genomic medicine, wireless health care and graduate medical education. With three highly respected graduate medical education programs, Scripps is a longstanding member of the Association of American Medical Colleges. More information can be found at www.scripps.org.
About Cypher Genomics
Cypher Genomics, Inc. is a company focusing on the interpretation and analysis of DNA sequence information for research, clinical, individual disease risk assessment, and forensic purposes. Cypher leverages both a suite of proprietary computational tools to interrogate the molecular effects of sequence variation as well as sophisticated methodology for consolidating disease risk and phenotype expression information for individual genomic health profile reporting. Cypher emerged from research pursued at The Scripps Translational Science Institute, Scripps Health and The Scripps Research Institute. More information can be found at: http://cyphergenomics.com/.
Certain statements in this press release, including statements relating to the ability of: research scientists to use the genomic data that Complete Genomics provides to help identify genetic variants and identify genetic bases for the health and lifespan of the Wellderly population, and the usefulness of the Wellderly Genomic Reference Resource for genomic based studies are forward-looking statements that are subject to risks and uncertainties. Readers are cautioned that these forward-looking statements are based on management's current expectations, and actual results may differ materially from those projected. The following factors, without limitation, could cause actual results to differ materially from those in the forward-looking statements: the ability of scientists to successfully analyze the genomic data we provide; and the ability of researchers to convert genomic data into medically valuable information. More information on potential risks and uncertainties is included in our Securities and Exchange Commission filings and reports, including the risks identified under the section captioned "Risk Factors" in our Quarterly Report on Form 10-Q filed on August 15, 2011. We disclaim any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.